| __timestamp | Agios Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 94231000 |
| Thursday, January 1, 2015 | 141827000 | 146394000 |
| Friday, January 1, 2016 | 220163000 | 188272000 |
| Sunday, January 1, 2017 | 292681000 | 166707000 |
| Monday, January 1, 2018 | 341324000 | 401843000 |
| Tuesday, January 1, 2019 | 410894000 | 560909000 |
| Wednesday, January 1, 2020 | 367470000 | 722343000 |
| Friday, January 1, 2021 | 256973000 | 771182000 |
| Saturday, January 1, 2022 | 279910000 | 877090000 |
| Sunday, January 1, 2023 | 288903000 | 877387000 |
| Monday, January 1, 2024 | 301286000 |
Infusing magic into the data realm
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Sarepta Therapeutics, Inc. and Agios Pharmaceuticals, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D). From 2014 to 2023, Sarepta consistently outpaced Agios, with R&D expenses growing by an impressive 830% compared to Agios's 190% increase. By 2023, Sarepta's R&D spending reached nearly three times that of Agios, highlighting its aggressive pursuit of groundbreaking therapies. This trend underscores Sarepta's commitment to innovation, particularly in the field of genetic medicine. Meanwhile, Agios, known for its focus on cellular metabolism, has maintained steady investment, reflecting a more conservative yet strategic approach. As these companies continue to innovate, their R&D investments will likely shape the future of biotech breakthroughs.
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs CymaBay Therapeutics, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
R&D Spending Showdown: MorphoSys AG vs Agios Pharmaceuticals, Inc.
Soleno Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Agios Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Allocate Funds